Literature DB >> 32694898

Low-depth whole genome sequencing reveals copy number variations associated with higher pathologic grading and more aggressive subtypes of lung non-mucinous adenocarcinoma.

Zheng Wang1, Lin Zhang1, Lei He1, Di Cui1, Chenglong Liu1, Liangyu Yin1, Min Zhang2, Lei Jiang2, Yuyan Gong3, Wang Wu3, Bi Liu3, Xiaoyu Li3, David S Cram3, Dongge Liu1.   

Abstract

OBJECTIVE: Histology grade, subtypes and TNM stage of lung adenocarcinomas are useful predictors of prognosis and survival. The aim of the study was to investigate the relationship between chromosomal instability, morphological subtypes and the grading system used in lung non-mucinous adenocarcinoma (LNMA).
METHODS: We developed a whole genome copy number variation (WGCNV) scoring system and applied next generation sequencing to evaluate CNVs present in 91 LNMA tumor samples.
RESULTS: Higher histological grades, aggressive subtypes and more advanced TNM staging were associated with an increased WGCNV score, particularly in CNV regions enriched for tumor suppressor genes and oncogenes. In addition, we demonstrate that 24-chromosome CNV profiling can be performed reliably from specific cell types (<100 cells) isolated by sample laser capture microdissection.
CONCLUSIONS: Our findings suggest that the WGCNV scoring system we developed may have potential value as an adjunct test for predicting the prognosis of patients diagnosed with LNMA.
Copyright © 2020 Chinese Journal of Cancer Research. All rights reserved.

Entities:  

Keywords:  Lung adenocarcinoma; TNM staging; copy number variations (CNVs); histological grading; lung non-mucinous adenocarcinoma (LNMA); whole genome copy number variation (WGCNV) score

Year:  2020        PMID: 32694898      PMCID: PMC7369181          DOI: 10.21147/j.issn.1000-9604.2020.03.05

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  41 in total

1.  DNA copy number aberrations associated with lymphovascular invasion in upper urinary tract urothelial carcinoma.

Authors:  Taku Misumi; Yoshiaki Yamamoto; Yoshihiro Miyachika; Satoshi Eguchi; Yasuyo Chochi; Motonao Nakao; Kazuhiro Nagao; Takahiko Hara; Shigeru Sakano; Tomoko Furuya; Atsunori Oga; Shigeto Kawauchi; Kohsuke Sasaki; Hideyasu Matsuyama
Journal:  Cancer Genet       Date:  2012-06

2.  Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer.

Authors:  Zhe-Wei Qiu; Jia-Hao Bi; Adi F Gazdar; Kai Song
Journal:  Genes Chromosomes Cancer       Date:  2017-05-04       Impact factor: 5.006

3.  Evaluation of grading systems in stage I lung adenocarcinomas: a retrospective cohort study.

Authors:  Tamás Zombori; József Furák; Tibor Nyári; Gábor Cserni; László Tiszlavicz
Journal:  J Clin Pathol       Date:  2017-07-26       Impact factor: 3.411

4.  A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Kei Suzuki; Stefan S Kachala; Emily C Zabor; Camelia S Sima; Andre L Moreira; Akihiko Yoshizawa; Gregory J Riely; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Mod Pathol       Date:  2012-04-13       Impact factor: 7.842

5.  Cribriform and fused glands are patterns of high-grade pulmonary adenocarcinoma.

Authors:  Andre L Moreira; Philippe Joubert; Robert J Downey; Natasha Rekhtman
Journal:  Hum Pathol       Date:  2013-10-23       Impact factor: 3.466

6.  Validation of copy number variation sequencing for detecting chromosome imbalances in human preimplantation embryos.

Authors:  Li Wang; David S Cram; Jiandong Shen; Xiaohong Wang; Jianguang Zhang; Zhuo Song; Genming Xu; Na Li; Junmei Fan; Shufang Wang; Yaning Luo; Jun Wang; Li Yu; Jiayin Liu; Yuanqing Yao
Journal:  Biol Reprod       Date:  2014-06-25       Impact factor: 4.285

7.  Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing.

Authors:  Yanlin Wang; Yan Chen; Feng Tian; Jianguang Zhang; Zhuo Song; Yi Wu; Xu Han; Wenjing Hu; Duan Ma; David Cram; Weiwei Cheng
Journal:  Clin Chem       Date:  2013-11-05       Impact factor: 8.327

8.  Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.

Authors:  Hideki Ujiie; Kyuichi Kadota; Jamie E Chaft; Daniel Buitrago; Camelia S Sima; Ming-Ching Lee; James Huang; William D Travis; Nabil P Rizk; Charles M Rudin; David R Jones; Prasad S Adusumilli
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

9.  Prediction for prognosis of resected pT1a-1bN0M0 adenocarcinoma based on tumor size and histological status: relationship of TNM and IASLC/ATS/ERS classifications.

Authors:  Masaoki Ito; Yoshihiro Miyata; Kei Kushitani; Tomoharu Yoshiya; Takahiro Mimae; Yuta Ibuki; Keizo Misumi; Yukio Takeshima; Morihito Okada
Journal:  Lung Cancer       Date:  2014-05-21       Impact factor: 5.705

10.  Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome.

Authors:  Teresa Davoli; Andrew Wei Xu; Kristen E Mengwasser; Laura M Sack; John C Yoon; Peter J Park; Stephen J Elledge
Journal:  Cell       Date:  2013-10-31       Impact factor: 41.582

View more
  3 in total

1.  Somatic copy number alterations are predictive of progression-free survival in patients with lung adenocarcinoma undergoing radiotherapy.

Authors:  Fan Kou; Lei Wu; Yan Guo; Bailu Zhang; Baihui Li; Ziqi Huang; Xiubao Ren; Lili Yang
Journal:  Cancer Biol Med       Date:  2021-08-27       Impact factor: 5.347

Review 2.  Cell-free DNA in the surveillance of heart transplant rejection.

Authors:  Dhruva Sharma; Ganapathy Subramaniam; Neha Sharma; Preksha Sharma
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-02-02

3.  Novel technologies in cfDNA analysis and potential utility in clinic.

Authors:  Jie Li; Mengyue Xu; Junya Peng; Jingqiao Wang; Yupei Zhao; Wenming Wu; Xun Lan
Journal:  Chin J Cancer Res       Date:  2021-12-31       Impact factor: 5.087

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.